-$0.38 Earnings Per Share Expected for Omeros Co. (NASDAQ:OMER) This Quarter

Brokerages forecast that Omeros Co. (NASDAQ:OMER) will post ($0.38) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Omeros’ earnings, with estimates ranging from ($0.47) to ($0.29). Omeros reported earnings of ($0.60) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 36.7%. The business is scheduled to issue its next quarterly earnings results on Thursday, August 8th.

On average, analysts expect that Omeros will report full year earnings of ($1.51) per share for the current financial year, with EPS estimates ranging from ($2.00) to ($0.68). For the next year, analysts expect that the company will report earnings of ($0.86) per share, with EPS estimates ranging from ($2.13) to $1.13. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow Omeros.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.04). The business had revenue of $21.80 million for the quarter, compared to analysts’ expectations of $23.18 million. Omeros’s revenue for the quarter was up 1271.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.62) earnings per share.

Several equities research analysts have issued reports on the stock. BidaskClub lowered shares of Omeros from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 11th. HC Wainwright set a $35.00 price target on shares of Omeros and gave the company a “buy” rating in a report on Tuesday, May 28th. Wedbush reissued a “hold” rating and issued a $18.00 price target on shares of Omeros in a report on Monday, May 20th. Zacks Investment Research lowered shares of Omeros from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Finally, ValuEngine lowered shares of Omeros from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. Omeros currently has a consensus rating of “Buy” and an average target price of $26.50.

Several institutional investors and hedge funds have recently bought and sold shares of OMER. Advisory Services Network LLC bought a new stake in shares of Omeros in the 1st quarter worth about $69,000. Legal & General Group Plc grew its holdings in shares of Omeros by 12.7% in the 4th quarter. Legal & General Group Plc now owns 8,370 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 945 shares during the last quarter. Keeley Teton Advisors LLC grew its holdings in shares of Omeros by 8.9% in the 4th quarter. Keeley Teton Advisors LLC now owns 13,001 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 1,060 shares during the last quarter. National Asset Management Inc. grew its holdings in shares of Omeros by 19.7% in the 4th quarter. National Asset Management Inc. now owns 15,180 shares of the biopharmaceutical company’s stock worth $170,000 after purchasing an additional 2,500 shares during the last quarter. Finally, BNP Paribas Arbitrage SA grew its holdings in shares of Omeros by 16,167.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 9,923 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 9,862 shares during the last quarter. 52.12% of the stock is currently owned by institutional investors and hedge funds.

Shares of Omeros stock opened at $16.97 on Tuesday. The firm has a market capitalization of $829.11 million, a price-to-earnings ratio of -7.64 and a beta of 3.41. Omeros has a 52-week low of $10.30 and a 52-week high of $27.00.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Story: Dividend Stocks – Are They Right For You?

Get a free copy of the Zacks research report on Omeros (OMER)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.